Dear Editor, In their short communication, Gomes et al. [1] provide interesting data on the real-life use of two antimuscarinic agents used in urinary incontinence. Nonetheless, in many countries around the world, these two agents are available in a range of formulations, as oxybutynin immediate-release (IR) tablets, extended release (ER) tablets, and transdermal patches; and as tolterodine IR tablets and ER capsules. Numerous studies suggest that the incidence of dry mouth, cited by patients as a common reason for treatment discontinuation, varies significantly between these formulations [2] [3] [4] . Consequently, the clinical value of the report by Gomes et al. would be greatly increased if the profile of oxybutynin and tolterodine formulations that comprise their data was described.
Yours sincerely, Angus Thompson 
